My scientist friends tell me China is paying well, making funding available, and has a lower go-to-market burden. Innovation appears to be literally moving to China as talent is being drained away from the US & Europe.

They have a lower go-to-market burden because the regulators don't much mind if you literally fabricate long-term clinical trial results out of whole cloth. The only innovation occurring is in the field of separating fools from their money.

Russia, too. http://www.cardiobrief.org/2017/04/26/serious-questions-rais...

I've seen how clinical trials take place here in India and yes, it's not always pretty. There are plenty of people who mean well and do good work, but the pressure to reduce cost invariably leads to shortcuts.

Just for biotech?

I'd count commodity electronics in there.

One factor is that by far the biggest profits are to be had in the US.

Maybe you can get approved in Australia or Sweden, but that will pay negligible sums compared to getting into the US market.

Could try for market pressure - for example, that male birth control being developed in India we keep hearing about. I bet it'll get approved here faster than normal because of how desired it is.

Related anecdote: to this day, in Japan access to the Pill remains limited because of vague "safety" concerns, despite decades of use. However, when Viagra appeared, it was approved in months...

Well, they do have a shrinking population problem...